A researcher from Stanford University asked IRP investigator Michael Ombrello, M.D., to help her team follow a new lead in the mystery of why some patients with a rare inflammatory condition called Still’s disease were coming down with a life-threatening lung ailment.
The recent observance in May of National Arthritis Awareness Month offered us a chance to reflect on a sizable component of the NIAMS mission area. Arthritis impacts the lives of nearly 60 million Americans. However, a recent conversation with David Wilson, Ph.D., director of NIH’s Tribal Health Research Office, reminded me that arthritis hits some communities harder than others.
NIBIB-funded researchers are developing an implantable, biodegradable film that helps to regenerate the native cartilage at the site of damage. Their study, performed in rabbits, could be an initial, important step in the establishment of a new treatment for this common condition, osteoarthritis.
The FDA approved Olumiant (baricitinib) oral tablets to treat adult patients with severe alopecia areata. The action marks the first FDA approval of a systemic treatment (i.e. treats the entire body rather than a specific location) for alopecia areata.
A recent 2-day NIH workshop aimed to better understand health disparities in caring for and treating people with osteoarthritis (OA) and the role played by social determinants of health. NIAMS, NIA and NIMHD sponsored the event.